Key facts
- This page summarizes Benjamin Kaplan's Form 4 filing for Mycotopia Therapies, Inc. (AIBT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 17 Dec 2024, 12:22.
Benjamin Kaplan - 13 Dec 2024 Form 4 Insider Report for Mycotopia Therapies, Inc. (AIBT)
- Reporting relationship
- CEO, Director
- Issuer ticker
- AIBT
- Reported as of
- 13 Dec 2024
- Net transaction value
- +$280,000
- SEC form
- 4
- Accepted by SEC
- 17 Dec 2024, 12:22:18 UTC
- Prior SEC filing
- 19 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Benjamin Kaplan
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Benjamin Kaplan filed Form 4 for Mycotopia Therapies, Inc. (AIBT) on 17 Dec 2024.
Change
- Previous filing in this sequence was filed on 19 Jul 2022.
- Current net transaction value: +$280,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TPIA
transaction
Common Stock
Award
- Transaction value
- $280,000
- Shares
- +20,000,000
- Change %
- +8000%
- Price
- $0.0140
- Shares after
- 20,250,000
- Date
- 13 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares received in lieu of cash for a portion of the filer's director's fees.